Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study

Piotr Adamski, Małgorzata Ostrowska, Joanna Sikora, Karolina Obońska, Katarzyna Buszko, Magdalena Krintus, Grażyna Sypniewska, Michał Piotr Marszałł, Marek Koziński, Jacek Kubica, Piotr Adamski, Małgorzata Ostrowska, Joanna Sikora, Karolina Obońska, Katarzyna Buszko, Magdalena Krintus, Grażyna Sypniewska, Michał Piotr Marszałł, Marek Koziński, Jacek Kubica

Abstract

Introduction: The most common classification of acute myocardial infarction (AMI) is based on electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). Both types of AMI differ concerning their epidemiology, clinical approach and early outcomes. Ticagrelor is a P2Y12 receptor inhibitor, constituting the first-line treatment for STEMI and NSTEMI. According to available data, STEMI may be associated with lower plasma concentration of ticagrelor in the first hours of AMI, but currently there are no studies directly comparing ticagrelor pharmacokinetics or antiplatelet effect in patients with STEMI versus NSTEMI.

Methods and analysis: The PINPOINT study is a phase IV, single-centre, investigator-initiated, prospective, observational study designed to compare the pharmacokinetics and pharmacodynamics of ticagrelor in patients with STEMI and NSTEMI assigned to the invasive strategy of treatment. Based on an internal pilot study, the trial is expected to include at least 23 patients with each AMI type. All subjects will receive a 180 mg loading dose of ticagrelor. The primary end point of the study is the area under the plasma concentration-time curve (AUC(0-6)) for ticagrelor during the first 6 hours after the loading dose. Secondary end points include various pharmacokinetic features of ticagrelor and its active metabolite (AR-C124910XX), and evaluation of platelet reactivity by the vasodilator-stimulated phosphoprotein assay and multiple electrode aggregometry. Blood samples for the pharmacokinetic and pharmacodynamic assessment will be obtained at pretreatment, 30 min, 1, 2, 3, 4, 6 and 12 hours post-ticagrelor loading dose.

Ethics and dissemination: The study received approval from the Local Ethics Committee (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; approval reference number KB 617/2015). The study results will be disseminated through conference presentations and peer-reviewed journals.

Trial registration number: NCT02602444; Pre-results.

Keywords: NSTEMI; STEMI; pharmacodynamics; pharmacokinetics; ticagrelor.

Conflict of interest statement

Competing interests: JK received a consulting fee from AstraZeneca. MK received honoraria for lectures from AstraZeneca. All other authors have reported no relationships relevant to the contents of this paper.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
The PINPOINT study schema. ASA, aspirin; LD, loading dose; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PD, pharmacodynamics; PK, pharmacokinetics; STEMI, ST-elevation myocardial infarction.
Figure 2
Figure 2
Platelet reactivity evaluation schedule for the PINPOINT study. GP IIb/IIIa, glycoprotein IIb/IIIa; MEA, multiple electrode aggregometry; VASP, vasodilator-stimulated phosphoprotein.

References

    1. Thygesen K, Alpert JS, Jaffe AS, et al. . Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551–67. 10.1093/eurheartj/ehs184
    1. Steg PG, James SK, Atar D, et al. . ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–619. 10.1093/eurheartj/ehs215
    1. Roffi M, Patrono C, Collet JP, et al. . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. 10.1093/eurheartj/ehv320
    1. Adamski P, Adamska U, Ostrowska M, et al. . New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother 2016;17:2291–306. 10.1080/14656566.2016.1241234
    1. Kubica J. The optimal antiplatelet treatment in an emergency setting. Folia Med Copernicana 2014;2:73–6.
    1. Aradi D, Kirtane A, Bonello L, et al. . Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36:1762–71. 10.1093/eurheartj/ehv104
    1. Winter MP, Koziński M, Kubica J, et al. . Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej 2015;11:259–80. 10.5114/pwki.2015.55596
    1. Navarese EP, Buffon A, Kozinski M, et al. . A critical overview on ticagrelor in acute coronary syndromes. QJM 2013;106:105–15. 10.1093/qjmed/hcs187
    1. Adamski P, Koziński M, Ostrowska M, et al. . Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost 2014;112:224–42. 10.1160/TH13-11-0915
    1. Teng R, Oliver S, Hayes MA, et al. . Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514–21. 10.1124/dmd.110.032250
    1. Husted S, Emanuelsson H, Heptinstall S, et al. . Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038–47. 10.1093/eurheartj/ehi754
    1. Varenhorst C, Eriksson N, Johansson Å, et al. . Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J 2015;36:1901–12. 10.1093/eurheartj/ehv116
    1. Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur J Clin Pharmacol 2012;68:1175–82. 10.1007/s00228-012-1227-4
    1. Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. J Clin Pharm Ther 2012;37:464–8. 10.1111/j.1365-2710.2011.01307.x
    1. Husted SE, Storey RF, Bliden K, et al. . Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet 2012;51:397–409. 10.2165/11599830-000000000-00000
    1. Hobl EL, Reiter B, Schoergenhofer C, et al. . Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest 2016;46:7–14. 10.1111/eci.12550
    1. Kubica J, Kubica A, Jilma B, et al. . Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol 2016;215:201–8. 10.1016/j.ijcard.2016.04.077
    1. Kubica J, Adamski P, Ostrowska M, et al. . Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016;37:245–52. 10.1093/eurheartj/ehv547
    1. Adamski P, Ostrowska M, Sroka WD, et al. . Does morphine administration affect ticagrelor conversion to its active metabolite in patients with acute myocardial infarction? A sub-analysis of the randomized, double-blind, placebo-controlled IMPRESSION trial. Folia Med Copernicana 2015;3:100–6.
    1. Franchi F, Rollini F, Cho JR, et al. . Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv 2015;8:1457–67. 10.1016/j.jcin.2015.02.030
    1. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010;66:487–96. 10.1007/s00228-009-0778-5
    1. Koziński M, Ostrowska M, Adamski P, et al. . Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC study. Thromb Haemost 2016;116:1140–9. 10.1160/TH16-07-0535
    1. Heestermans AA, van Werkum JW, Taubert D, et al. . Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008;122:776–81. 10.1016/j.thromres.2008.01.021
    1. Kubica J, Kozinski M, Navarese EP, et al. . Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin 2014;30:813–28. 10.1185/03007995.2014.880050
    1. Parodi G, Valenti R, Bellandi B, et al. . Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601–6. 10.1016/j.jacc.2013.01.024
    1. Wallentin L, Becker RC, Budaj A, et al. . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57. 10.1056/NEJMoa0904327
    1. McManus DD, Gore J, Yarzebski J, et al. . Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011;124:40–7. 10.1016/j.amjmed.2010.07.023
    1. Gierlotka M, Zdrojewski T, Wojtyniak B, et al. . Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009–2012-nationwide AMI-PL database. Kardiol Pol 2015;73:142–58. 10.5603/KP.a2014.0213
    1. Mandelzweig L, Battler A, Boyko V, et al. . The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean basin in 2004. Eur Heart J 2006;27:2285–93. 10.1093/eurheartj/ehl196
    1. Terkelsen CJ, Lassen JF, Norgaard BL, et al. . Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. Eur Heart J 2005;26:18–26.
    1. Kubica J, Adamski P, Ostrowska M, et al. . Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials 2015;16:198 10.1186/s13063-015-0724-z
    1. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:2299–306. 10.1016/j.jchromb.2010.06.018
    1. Kubica A, Kasprzak M, Siller-Matula J, et al. . Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol 2014;742:47–54. 10.1016/j.ejphar.2014.08.009
    1. Koziński M, Obońska K, Stankowska K, et al. . Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J 2014;21:547–56. 10.5603/CJ.a2014.0026
    1. Aradi D, Storey RF, Komócsi A, et al. . Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014;35: 209–15. 10.1093/eurheartj/eht375
    1. Windecker S, Kolh P, Alfonso F, et al. , Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS): Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–619. 10.1093/eurheartj/ehu278

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する